In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction
(HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with …

Heart failure (HF) is responsible for substantial morbidity and mortality and is increasing in
prevalence. Although there has been remarkable progress in the treatment of HF with …

Aims This pilot study aimed to assess the potential benefits of cardiac contractility
modulation (CCM) in patients with heart failure with preserved ejection fraction (HFpEF) …

The new guidelines classify heart failure (HF) into three subgroups based on the ejection
fraction (EF): HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with …

Heart failure is a major health problem worldwide and, despite effective therapies, is
expected to grow by almost 50% over the next 15 years. Five-year mortality remains high at …

Reversible post-translational modifications of various cardiac proteins regulate the
mechanical properties of the cardiomyocytes and thus modulate the contractile performance …

About 50% of all patients suffering from heart failure (HF) exhibit a reduced ejection fraction
(EF≤ 40%), termed HFrEF. The others may be classified into HF with midrange EF (HFmrEF …

In heart failure with reduced ejection fraction and heart failure with preserved ejection
fraction, profound cellular and molecular changes have recently been documented in the …

Historically, only patients with a left ventricular ejection fraction (LVEF) of less than or equal
to 40% were considered to have heart failure (HF). However, it was later found that patients …

Abstract Backgroun/Aims: To explore the effect of cardiac contractility modulation (CCM) on
myocardial fibrosis in heart failure and to investigate the underlying mechanism. Methods …